A citation-based method for searching scientific literature

Richard Furie, Munther Khamashta, Joan T Merrill, Victoria P Werth, Kenneth Kalunian, Philip Brohawn, Gabor G Illei, Jorn Drappa, Liangwei Wang, Stephen Yoo. Arthritis Rheumatol 2017
Times Cited: 336







List of co-cited articles
1002 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
Munther Khamashta, Joan T Merrill, Victoria P Werth, Richard Furie, Kenneth Kalunian, Gabor G Illei, Jorn Drappa, Liangwei Wang, Warren Greth. Ann Rheum Dis 2016
246
50

Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
Eric F Morand, Richard Furie, Yoshiya Tanaka, Ian N Bruce, Anca D Askanase, Christophe Richez, Sang-Cheol Bae, Philip Z Brohawn, Lilia Pineda, Anna Berglind,[...]. N Engl J Med 2020
156
35

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
Kenneth C Kalunian, Joan T Merrill, Romeo Maciuca, Jacqueline M McBride, Michael J Townsend, Xiaohui Wei, John C Davis, William P Kennedy. Ann Rheum Dis 2016
191
30

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.
Emily C Baechler, Franak M Batliwalla, George Karypis, Patrick M Gaffney, Ward A Ortmann, Karl J Espe, Katherine B Shark, William J Grande, Karis M Hughes, Vivek Kapur,[...]. Proc Natl Acad Sci U S A 2003
27

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood.
Lynda Bennett, A Karolina Palucka, Edsel Arce, Victoria Cantrell, Josef Borvak, Jacques Banchereau, Virginia Pascual. J Exp Med 2003
25

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Sandra V Navarra, Renato M Guzmán, Alberto E Gallacher, Stephen Hall, Roger A Levy, Renato E Jimenez, Edmund K-M Li, Mathew Thomas, Ho-Youn Kim, Manuel G León,[...]. Lancet 2011
917
24

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Daniel J Wallace, Richard A Furie, Yoshiya Tanaka, Kenneth C Kalunian, Marta Mosca, Michelle A Petri, Thomas Dörner, Mario H Cardiel, Ian N Bruce, Elisa Gomez,[...]. Lancet 2018
151
23

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
Ronald F van Vollenhoven, Bevra H Hahn, George C Tsokos, Carrie L Wagner, Peter Lipsky, Zahi Touma, Victoria P Werth, Robert M Gordon, Bei Zhou, Benjamin Hsu,[...]. Lancet 2018
115
22

Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.
Richard Furie, Victoria P Werth, Joseph F Merola, Lauren Stevenson, Taylor L Reynolds, Himanshu Naik, Wenting Wang, Romy Christmann, Agnes Gardet, Alex Pellerin,[...]. J Clin Invest 2019
72
27

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Richard Furie, Michelle Petri, Omid Zamani, Ricard Cervera, Daniel J Wallace, Dana Tegzová, Jorge Sanchez-Guerrero, Andreas Schwarting, Joan T Merrill, W Winn Chatham,[...]. Arthritis Rheum 2011
720
19

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
Joan T Merrill, C Michael Neuwelt, Daniel J Wallace, Joseph C Shanahan, Kevin M Latinis, James C Oates, Tammy O Utset, Caroline Gordon, David A Isenberg, Hsin-Ju Hsieh,[...]. Arthritis Rheum 2010
650
17

Systemic lupus erythematosus.
George C Tsokos. N Engl J Med 2011
15

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Antonis Fanouriakis, Myrto Kostopoulou, Alessia Alunno, Martin Aringer, Ingeborg Bajema, John N Boletis, Ricard Cervera, Andrea Doria, Caroline Gordon, Marcello Govoni,[...]. Ann Rheum Dis 2019
308
14

The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus.
Joerg Albrecht, Lynne Taylor, Jesse A Berlin, Samuel Dulay, Gina Ang, Steven Fakharzadeh, Jonathan Kantor, Ellen Kim, Giuseppe Militello, Karen McGinnis,[...]. J Invest Dermatol 2005
227
14

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
Brad H Rovin, Richard Furie, Kevin Latinis, R John Looney, Fernando C Fervenza, Jorge Sanchez-Guerrero, Romeo Maciuca, David Zhang, Jay P Garg, Paul Brunetta,[...]. Arthritis Rheum 2012
628
14


Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
Kyriakos A Kirou, Christina Lee, Sandhya George, Kyriakos Louca, Margaret G E Peterson, Mary K Crow. Arthritis Rheum 2005
432
12


Regulation of type I interferon responses.
Lionel B Ivashkiv, Laura T Donlin. Nat Rev Immunol 2014
11

Brief Report: Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti-Interferon-γ Antibody, in Patients With Discoid Lupus Erythematosus.
Victoria P Werth, David Fiorentino, Barbara A Sullivan, Michael J Boedigheimer, Kit Chiu, Christine Wang, Gregory E Arnold, Michael A Damore, Jeannette Bigler, Andrew A Welcher,[...]. Arthritis Rheumatol 2017
38
28


Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.
Daniel J Wallace, Kenneth Kalunian, Michelle A Petri, Vibeke Strand, Frederic A Houssiau, Marilyn Pike, Brian Kilgallen, Sabine Bongardt, Anna Barry, Lexy Kelley,[...]. Ann Rheum Dis 2014
157
11

Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.
Jeffrey M Riggs, Richard N Hanna, Bhargavi Rajan, Kamelia Zerrouki, Jodi L Karnell, Divya Sagar, Inna Vainshtein, Erika Farmer, Kimberly Rosenthal, Chris Morehouse,[...]. Lupus Sci Med 2018
30
36

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
Jacqueline M McBride, Jenny Jiang, Alexander R Abbas, Alyssa Morimoto, Jing Li, Romeo Maciuca, Michael Townsend, Daniel J Wallace, William P Kennedy, Jorn Drappa. Arthritis Rheum 2012
122
10

Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease.
Christian Lood, Luz P Blanco, Monica M Purmalek, Carmelo Carmona-Rivera, Suk S De Ravin, Carolyne K Smith, Harry L Malech, Jeffrey A Ledbetter, Keith B Elkon, Mariana J Kaplan. Nat Med 2016
513
10

Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus.
Gina S Garcia-Romo, Simone Caielli, Barbara Vega, John Connolly, Florence Allantaz, Zhaohui Xu, Marilynn Punaro, Jeanine Baisch, Cristiana Guiducci, Robert L Coffman,[...]. Sci Transl Med 2011
717
10

Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus.
Roberto Lande, Dipyaman Ganguly, Valeria Facchinetti, Loredana Frasca, Curdin Conrad, Josh Gregorio, Stephan Meller, Georgios Chamilos, Rosalie Sebasigari, Valeria Riccieri,[...]. Sci Transl Med 2011
732
10

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus.
Joan T Merrill, Richard Furie, Victoria P Werth, Munther Khamashta, Jorn Drappa, Liangwei Wang, Gabor Illei, Raj Tummala. Lupus Sci Med 2018
23
43

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
Megan E B Clowse, Daniel J Wallace, Richard A Furie, Michelle A Petri, Marilyn C Pike, Piotr Leszczyński, C Michael Neuwelt, Kathryn Hobbs, Mauro Keiserman, Liliana Duca,[...]. Arthritis Rheumatol 2017
81
12

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.
Ronald F van Vollenhoven, Marta Mosca, George Bertsias, David Isenberg, Annegret Kuhn, Kirsten Lerstrøm, Martin Aringer, Hendrika Bootsma, Dimitrios Boumpas, Ian N Bruce,[...]. Ann Rheum Dis 2014
282
10

IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study.
Frederic A Houssiau, Aikaterini Thanou, Minodora Mazur, Edgar Ramiterre, Danny Alexis Gomez Mora, Maria Misterska-Skora, Risto Alfredo Perich-Campos, Svetlana A Smakotina, Sergio Cerpa Cruz, Bassem Louzir,[...]. Ann Rheum Dis 2020
19
52

Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody.
Li Peng, Vaheh Oganesyan, Herren Wu, William F Dall'Acqua, Melissa M Damschroder. MAbs 2015
51
17

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.
Michelle Petri, Daniel J Wallace, Alberto Spindler, Vishala Chindalore, Kenneth Kalunian, Eduardo Mysler, C Michael Neuwelt, Gabriel Robbie, Wendy I White, Brandon W Higgs,[...]. Arthritis Rheum 2013
170
9

Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus.
Eneida Villanueva, Srilakshmi Yalavarthi, Celine C Berthier, Jeffrey B Hodgin, Ritika Khandpur, Andrew M Lin, Cory J Rubin, Wenpu Zhao, Stephen H Olsen, Matthew Klinker,[...]. J Immunol 2011
627
9

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
William Stohl, Andreas Schwarting, Masato Okada, Morton Scheinberg, Andrea Doria, Anne E Hammer, Christi Kleoudis, James Groark, Damon Bass, Norma Lynn Fox,[...]. Arthritis Rheumatol 2017
111
9

Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients.
Romain Banchereau, Seunghee Hong, Brandi Cantarel, Nicole Baldwin, Jeanine Baisch, Michelle Edens, Alma-Martina Cepika, Peter Acs, Jacob Turner, Esperanza Anguiano,[...]. Cell 2016
224
9


Type I interferon in rheumatic diseases.
Theresa L Wampler Muskardin, Timothy B Niewold. Nat Rev Rheumatol 2018
75
10

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study.
Avram Goldberg, Thomas Geppert, Elena Schiopu, Tracy Frech, Vivien Hsu, Robert W Simms, Stanford L Peng, Yihong Yao, Nairouz Elgeioushi, Linda Chang,[...]. Arthritis Res Ther 2014
41
19

Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study.
Julie Ducreux, Frédéric A Houssiau, Pierre Vandepapelière, Christian Jorgensen, Estibaliz Lazaro, François Spertini, Fabien Colaone, Camille Roucairol, Marion Laborie, Thérèse Croughs,[...]. Rheumatology (Oxford) 2016
42
19

Targeting interferons and their pathways in systemic lupus erythematosus.
François Chasset, Laurent Arnaud. Autoimmun Rev 2018
60
13


Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).
Kate Franklyn, Chak Sing Lau, Sandra V Navarra, Worawit Louthrenoo, Aisha Lateef, Laniyati Hamijoyo, C Singgih Wahono, Shun Le Chen, Ou Jin, Susan Morton,[...]. Ann Rheum Dis 2016
163
8

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Michelle Petri, Ana-Maria Orbai, Graciela S Alarcón, Caroline Gordon, Joan T Merrill, Paul R Fortin, Ian N Bruce, David Isenberg, Daniel J Wallace, Ola Nived,[...]. Arthritis Rheum 2012
8

Novel evidence-based systemic lupus erythematosus responder index.
Richard A Furie, Michelle A Petri, Daniel J Wallace, Ellen M Ginzler, Joan T Merrill, William Stohl, W Winn Chatham, Vibeke Strand, Arthur Weinstein, Marc R Chevrier,[...]. Arthritis Rheum 2009
250
8


Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study.
Richard Furie, Kathy Nicholls, Tien-Tsai Cheng, Frederic Houssiau, Ruben Burgos-Vargas, Shun-Le Chen, Jan L Hillson, Stephanie Meadows-Shropshire, Michael Kinaszczuk, Joan T Merrill. Arthritis Rheumatol 2014
178
8

Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa.
Mrinal K Sarkar, Grace A Hile, Lam C Tsoi, Xianying Xing, Jianhua Liu, Yun Liang, Celine C Berthier, William R Swindell, Matthew T Patrick, Shuai Shao,[...]. Ann Rheum Dis 2018
55
14

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.
Ian N Bruce, Aidan G O'Keeffe, Vern Farewell, John G Hanly, Susan Manzi, Li Su, Dafna D Gladman, Sang-Cheol Bae, Jorge Sanchez-Guerrero, Juanita Romero-Diaz,[...]. Ann Rheum Dis 2015
193
7

Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.
P Blanco, A K Palucka, M Gill, V Pascual, J Banchereau. Science 2001
876
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.